List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary AbstractThe EPA maintains a Toxics Release Inventory of andgttoxic chemicals that are disposed or released from andgtindustrial sites in the United Stateswhile HHS and USDA maintain a list of overselect agents and toxicants that pose a severe risk to humananimaland plant healthThese compounds represent only a fraction of the known and unknown environmental toxicants that may advers ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Noninvasive Home Assessment of Cardiac Filling Pressure to Identify Heart Failure Patients at High Risk for Readmission

    SBC: Vixiar Medical, Inc            Topic: NHLBI

    Congestive heart failureCHFis the most common reason for hospitalization in the U Swith overmillion admissions per yearPatients admitted with CHF usually need IV diuretics to promote fluid removalThe readmission rate is highoverbydaysandbydays post dischargeThis also presents an enormous economic burdenhospitalizations account for a large percentage of the $billion spent yearly on heart failureOne ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel sanitizer/disinfectants against viral infections with long-lasting effect

    SBC: CAMELLIX, LLC            Topic: NIAID

    AbstractNorovirus is the most common cause of acute gastroenteritis in the United Statesassociated annually withmillion illnesseshospitalizations anddeathsUS CDCOverview about NorovirusNorovirus is one of the nonenveloped viruses that are resistant to alcohol sanitizationAccording to US CDC Guidelines for the Prevention and Control of Norovirus Gastroenteritis Outbreaks in Healthcare Settingsthe p ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. BlueBox: A Complete Code Blue Data Recorder, Phase II

    SBC: NeoVative, Inc.            Topic: 400

    Code blueis the signal used in hospitals to call for an immediate cardiopulmonary resuscitationCPRfollowing a cardiac or respiratory arrestReviewing the performance of thecode blue teamis a cornerstone for improving outcomesThe current standard of using handwritten records on a papercode sheetdoes not allow measurement of key quality indicators and is subject to human errorIn the Phase I STTR proj ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Automated point-of-care identification of innocent Still's murmur in children

    SBC: AUSCULTECH DX LLC            Topic: NHLBI

    PROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low costpoint of caremobile device based technology for automated identification of Stillandapos s murmurthe most common innocentbenign and harmlessheart murmur of childhoodThis novel technology could reduce the current rate of over half a million children unnecessarily referred to pediatric ca ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY GlioblastomaGBMis an intractable cancer with an average survival time oftomonthsTreatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrierbut engineered neural stem cellsNSCshold great promise as GBM therapies because they selectively migrate to tumor cells and can ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Oxidation-resistant Anti-protease Therapy

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosisIPFthe most common of the interstitial lung diseasesoccurs in aboutpeoplewithnew cases diagnosed annually in the USThe typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandaposof the lungs causing an irreversible loss of the tissueandapos s ability to transport oxygenCo morbid pulmonary hypertension is commonly seen in ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Development of OCF001 for Treatment of Yeast Infections

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary OccidiofunginsA Dare cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungiOptimization of the production and isolation of occidiofungins from liquid cultures has been performedThe production and isolation of predominantly one analogcalled occidiofungin BOCFsupports its commercial development as a novel antifun ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government